

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING D	ATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/076,191 02/14/2002		Craig P. Smith	USAV2001/0002 US NP	8943	
5487	7590 0	05/09/2003			
ROSS J. OE			EXAMINER		
AVENTIS PHARMACEUTICALS INC. ROUTE 202-206				JONES, DWAYNE C	
MAIL CODE					
	TER, NJ 0880)7	ART UNIT	PAPER NUMBER	
	•			1614	
				DATE MAILED: 05/09/2003	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/076,191	SMITH ET AL.					
Office Action Summary	Examiner	Art Unit					
	Dwayne C Jones	1614					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be within the statutory minimum of thirty (30) of the apply and will expire SIX (6) MONTHS from cause the application to become ABANDO	timely filed lays will be considered timely. om the mailing date of this communication. NED (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on							
2a) ☐ This action is FINAL . 2b) ☐ Thi	is action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
 4) ☐ Claim(s) 1-33 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 							
· · · · · · · · · · · · · · · · · · ·	vii iloiti consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
	7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1-33</u> are subject to restriction and/or election requirement. Application Papers							
	•						
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
<u> </u>	s have been received						
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language pro	visional application has been r	eceived.					
Attachment(s)	2 priority aridor 00 0.0.0. 33 1	20 0.10.01 12 1.					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Information	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)					
	· 						

Application/Control Number: 10/076,191

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

- Restriction to one of the following inventions is required under 35 U.S.C.
 121:
 - Claims 1-7,11,21,22, drawn to a method of treating the demyelinating disease of multiple sclerosis, classified in class 514, subclasses 323 and 903.
 - II. Claims 8, 12, 23, drawn to a method of treating spinal cord injury, classified in class 514, subclass 323.
 - III. Claims 9,13,24, drawn to a method treating traumatic brain injury, classified in class 514, subclass 323.
 - IV. Claims 10,14-17,25, drawn to a method of treating stroke, classified in class 514, subclass 323.
 - V. Claims 18-19, drawn to a method of blocking K+ channel activity, classified in class 514, subclass 323.
 - VI. Claims 26-27, drawn to a method of treating neuropathic pain, classified in class 514, subclass 323.
 - VII. Claims 28,29, drawn to a method of treating bladder infection, classified in class 514, subclass 323.
 - VIII. Claims 30,31, drawn to a method of treating over active bladder, classified in class 514, subclass 323.

Application/Control Number: 10/076,191

Art Unit: 1614

IX. Claims 32-33, drawn to a method of treating chemokine-induced pain, classified in class 514, subclass 323.

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions (I-IX) and (I-IX) are unrelated. Inventions are unrelated if it can be shown that they have different modes of operation, different functions, or different effects. In the instant case the different inventions, a method of treating bladder infections and overactive bladder has different effects affects than treating an injury of the spinal cord, or multiple sclerosis or stroke. For example, multiple sclerosis can be treated with 4-amino pyridine, whereas stroke can be treated with heparin and coumarin derivatives and urinary infection may be treated with septra.
- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 4. A telephone call to the attorney is not required where: 1) the restriction requirement is complex, 2) the application is being prosecuted pro se, or 3) the examiner knows from past experience that a telephone election will not be made, see MPEP Sect. 812.01.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b)

Application/Control Number: 10/076,191

Art Unit: 1614

if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

DWAYNE'C. JONES PRIMARY EXAMINER

Tech. Ctr. 1614

May 8, 2003